<SEC-DOCUMENT>0001104659-19-053570.txt : 20191118
<SEC-HEADER>0001104659-19-053570.hdr.sgml : 20191118
<ACCEPTANCE-DATETIME>20191009160609
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-19-053570
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20191009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>


<html>
<head>







  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="459" height="124" src="g197811bei001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">October&nbsp;9, 2019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Mark Brunhofer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ms.&nbsp;Sharon Blume</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Office of Healthcare&nbsp;&amp; Insurance</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">United States Securities and Exchange Commission</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Division of Corporation Finance</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100 F Street, N.E.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington, DC 20549</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re:</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PTC Therapeutics,&nbsp;Inc.</b></p>
<p style="margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;10-K for the Fiscal Year Ended December&nbsp;31, 2018</font></b></p>
<p style="margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Filed March&nbsp;1, 2019</font></b></p>
<p style="margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">File No.&nbsp;001-35969</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Mr.&nbsp;Brunhofer and Ms.&nbsp;Blume:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This letter is submitted on behalf of PTC Therapeutics,&nbsp;Inc. (the &#147;Company&#148; or &#147;PTC&#148;) in response to a written comment of the Staff (the &#147;Staff&#148;) of the Securities and Exchange Commission (the &#147;Commission&#148;) in the letter dated September&nbsp;26, 2019 (the &#147;Comment Letter&#148;) with respect to the Company&#146;s Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018, as filed with the Commission on March&nbsp;1, 2019 (the &#147;2018 Form&nbsp;10-K&#148;). The Staff&#146;s comment is reproduced below and the Company&#146;s corresponding response follows accordingly.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Form&nbsp;10-K for the Fiscal Year Ended December&nbsp;31, 2018</font></u></i></b></p>
<p style="margin:0in 0in .0001pt;"><b><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Notes to consolidated financial statements</font></u></i></b></p>
<p style="margin:0in 0in .0001pt;"><b><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Note 13: Income taxes, page&nbsp;171</font></u></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">1.</font></i></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">On page&nbsp;173 you disclose that the deferred tax liability associated with the in-process research and development intangible asset from your acquisition of Agilis Biotherapeutics,&nbsp;Inc. is not considered positive evidence of future income in part because it is an indefinite-lived intangible asset.&#160; Please tell us why you did not record some income tax benefit outside acquisition accounting under ASC 805-740-30-3 associated with any net operating loss generated in 2018.&#160; In this regard, we note that net operating losses since the enactment of the Tax Cuts and Jobs Act do not expire.&#160; In your response, tell us the amount of net operating loss generated in 2018.&#160; Reference for us the authoritative literature you rely upon to support your accounting.</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C905684\19-19781-1\task9505947\19781-1-be.htm',USER='C905684',CD='Oct  9 01:16 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Response:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company acknowledges the guidance in ASC 805-740-30-3 which notes that an</font> acquirer may be able to utilize the benefit of its tax operating loss carryforwards against the future taxable profit of the acquiree and reduce its valuation allowance based on the weight of available evidence.&#160; This should be accounted for as an event separate from the business combination; recognized as an element of the acquirer&#146;s deferred income tax expense (benefit) in the reporting period that includes the business combination. However, since the Company generated taxable income for U.S. tax purposes in 2018 of $5.8 million, and as such did not generate any net operating losses in 2018, the Company does not believe this guidance is applicable since the Company does not have any net operating loss carryforwards since the enactment of the 2017 Tax Cuts and Jobs Act to utilize. As a result, the Company did not record any income tax benefit outside of the acquisition.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*&#160; *&#160; *</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thank you for your consideration of our response to your comments.</font> Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (908) 912-9327.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sincerely,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PTC Therapeutics,&nbsp;Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Emily Hill</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emily   Hill</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C905684\19-19781-1\task9505947\19781-1-be.htm',USER='C905684',CD='Oct  9 01:16 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g197811bei001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197811bei001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !\ <L# 2(  A$! Q$!_\0
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M=AI7+%%)GVHS3$+129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
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M<-'8"6*39N9?G&. 35-[R5&=8+HSH-N7('RDGIQ[4 6?[-<XE:?-SN#!]O'
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M[NF>/UK=I:5W>X&#H6B:II\TQU/6GU")TVK&T87;[U@?\*VFQ]B&L2#1O/\
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MH ***.: "G4WM^M.H 0TE.I,4 )WH_"EQ1B@!/P_.CZTN* ,4 )^M'X4M&*
M$Q1Q2XHQ0 G%'TI<48H 3/Y4>U.I,4 )CVHI<"C% "44N*,4 )^%%+BB@!**
M7'&*,4 )12T8H 3K1FEQ1B@!/I1G]*7%&,T )12T8H 2H'!-]"<'&QN?RJQB
MC%)JXT["8H_I2XHQ3$)_2CI3J2@!/QQ12T4 )13J3% "<^U%+1B@!**7%&!0
M E%+BC% "?YXH]Z7%&* $HQFEHH 2C^=+@48% "=*.O44N!1@4 )1_G%+BB@
)!*=28I: /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
